Company news
BridgeBio Pharma, Inc. news in 2020
BridgeBio Pharma, Inc.'s news releases, calls and decks from 2020, newest first.
BridgeBio Pharma and Maze Therapeutics Establish Joint Venture to Advance Precision Medicine to Treat Cardiovascular Disease
December 6, 2020
BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma
November 30, 2020
BridgeBio Pharma and Affiliate Navire Pharma Announce Dosing of First Patient in Phase 1 Clinical Trial of SHP2 inhibitor BBP-398 for Tumors Driven by RAS and Receptor Tyrosine Kinase Mutations
November 12, 2020
BridgeBio Pharma, Inc. Reports Third Quarter 2020 Financial Results And Business Update
November 4, 2020
BridgeBio Pharma and Affiliate Phoenix Tissue Repair Announce First Patient Dosing In Phase 2 Trial of Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
October 26, 2020
BridgeBio Pharma, Inc. and the University of Colorado Anschutz Medical Campus Collaborate to Advance Medicines for Genetically Driven Diseases
October 20, 2020
BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement
October 4, 2020
BridgeBio Pharma and Affiliate Origin Biosciences Announces FDA Acceptance of its New Drug Application for Fosdenopterin for the Treatment of MoCD Type A
September 28, 2020
BridgeBio Pharma to Host Virtual R&D Day on September 29, 2020
September 21, 2020
BridgeBio Pharma’s Calcilytix Therapeutics Initiates Phase 2 Study Of Encaleret For Autosomal Dominant Hypocalcemia Type 1 (ADH1)
September 20, 2020
BridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results and Business Update
August 10, 2020
BridgeBio Pharma’s QED Therapeutics Doses First Child in Phase 2 Clinical Trial of the Investigational Medicine Infigratinib in Achondroplasia
July 14, 2020
BridgeBio Pharma, Inc. Appoints Biotech Trailblazers Brent Saunders and Randy Scott and Renowned Economist Andrew Lo to Board of Directors
June 23, 2020
BridgeBio Pharma and University of Florida Establish Collaboration to Advance Therapies for Genetically Driven Diseases
June 17, 2020
BridgeBio Pharma’s ML Bio Solutions Announces Dosing of First Subject in Phase 1 Clinical Trial of BBP-418 For Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
June 10, 2020
BridgeBio Pharma, Inc. Reports First Quarter 2020 Financial Results and Business Update
May 12, 2020
BridgeBio Pharma’s QED Therapeutics Announces Preclinical Data Demonstrating Potential of Low-Dose Infigratinib in Achondroplasia
May 10, 2020
BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations
March 11, 2020
BridgeBio Pharma, Inc. Announces Proposed Offering of $350 Million Convertible Senior Notes
March 3, 2020
BridgeBio Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Portfolio Progress
March 1, 2020
BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board of Directors
February 23, 2020
BridgeBio Pharma Grows Pipeline to 20+ Genetic Medicines with Four Assets Focused on Treating Genetically Driven Diseases at Their Source
January 12, 2020
BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity
January 9, 2020
BridgeBio Pharma’s QED Therapeutics Receives Fast Track Designation for Infigratinib in Adults with First-Line Advanced or Metastatic Cholangiocarcinoma and Orphan Drug Designation for Infigratinib for Treatment of Cholangiocarcinoma
January 5, 2020
Decks in 2020
- Merger or Acquisition (October 2020)
Merger or acquisition · 12 slides · Oct 5, 2020
- Investor Day (September 2020)
Investor day · 24 slides · Sep 29, 2020